Company Filing History:
Years Active: 2018-2020
Title: Innovations by Andrew Nolan in Ocular Modelling
Introduction
Andrew Nolan is an accomplished inventor based in Louth, Ireland. He has made significant contributions to the field of ocular modelling, holding two patents that showcase his innovative approach to understanding eye parameters. His work is particularly relevant in the context of advancing medical technology and improving patient outcomes.
Latest Patents
Andrew Nolan's latest patents include an "Apparatus for modelling ocular structures." This apparatus is designed for motion-compensated modelling of a parameter of the eye. It comprises a first measuring means for assessing a plurality of position parameters of the eye concerning an optical reference coordinate system. Additionally, it features a second measuring means for capturing an interference signal at various optical reference coordinates. The measurements of the position parameters and the interference signal are time-synchronized. The apparatus also includes means for correcting the interference signal to account for displacements of the parameters and means for modelling the eye parameter based on the corrected interference signal.
Career Highlights
Andrew Nolan has established himself as a key figure in the field of ocular research. His work at Novartis AG has allowed him to collaborate with leading experts and contribute to groundbreaking advancements in eye care technology. His patents reflect a deep understanding of both the technical and practical aspects of ocular modelling.
Collaborations
Andrew has worked alongside notable colleagues such as Daniel Boss and Michael Mrochen. Their combined expertise has fostered an environment of innovation and collaboration, leading to significant advancements in ocular technology.
Conclusion
In summary, Andrew Nolan's contributions to ocular modelling through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in eye care technology, ultimately benefiting patients and the medical community.